Biology, asked by Anonymous, 11 months ago

As a Corona is missuse of Biotechnology or against biosafety , then what will be effect on Biotechnology or on scope of biotech after this ?​

Answers

Answered by sreyassanker123462
0

Answer:

Explanation:

The Department of Biotechnology (DBT) under the India chapter of ... development against the Nipah virus for the novel coronavirus too. Pune-based Serum Institute could work on the monoclonal antibody ... “Understanding the disease, its reservoirs, transmission and clinical severity and then developing

Answered by padmavathibolla
5

Answer:

Biotech department set to work on vaccines for coronavirus

The Department of Biotechnology (DBT) under the India chapter of the Coalition of Epidemic Preparedness and Innovations (CEPI) will support Indian companies aligned to the development of vaccines against the Covid-19 and other emerging infectious ...

MUMBAI: The Department of Biotechnology (DBT) on Tuesday said it was partnering with the Norway-based Coalition of Epidemic Preparedness and Innovations (CEPI) to fund development of vaccines for the novel coronavirus (Covid-19).

The DBT under the India chapter of the CEPI will support Indian companies aligned to the development of vaccines against the Covid-19 and other emerging infectious diseases.

“We will be providing top-up funding for companies in India who apply for the CEPI call and also give access to our larger ecosystem and networks,” DBT secretary Renu Swarup told ET. Swarup added that the funding would be given case by case and this would come from the common pool of fund that the department had assigned for vaccine development.

DBT is putting together a network of organisations globally who are working on better diagnostics to detect the infection and also possible monoclonal antibodies. Sources who are aware of the development said there was a possibility of extending the vaccine that was under development against the Nipah virus for the novel coronavirus too. Pune-based Serum Institute could work on the monoclonal antibody pathway. Its chief executive Adar Poonawala offered “no comments” when asked about it.

I HOPE IT'S HELPS YOU

Similar questions